ARCA biopharma Inc. (NASDAQ: ABIO)
$3.49
+0.1350 ( +4.03% ) 315.6K
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
Market Data
Open
$3.49
Previous close
$3.35
Volume
315.6K
Market cap
$50.48M
Day range
$3.42 - $3.64
52 week range
$1.56 - $4.49
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 13 | Apr 04, 2024 |
8-k | 8K-related | 52 | Apr 03, 2024 |
8-k | 8K-related | 52 | Apr 03, 2024 |
8-k | 8K-related | 12 | Mar 22, 2024 |
8-k | 8K-related | 12 | Mar 22, 2024 |
8-k | 8K-related | 12 | Feb 06, 2024 |
8-k | 8K-related | 12 | Feb 06, 2024 |
8-k | 8K-related | 14 | Feb 01, 2024 |
8-k | 8K-related | 14 | Feb 01, 2024 |
10-k | Annual reports | 61 | Feb 01, 2024 |